- Home
- IGMS vs QUIK Comparison
IGMS vs QUIK Comparison
Compare IGMS & QUIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- QUIK
- Stock Information
- Founded
- IGMS 1993
- QUIK 1988
- Country
- IGMS United States
- QUIK United States
- Employees
- IGMS N/A
- QUIK N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- QUIK Semiconductors
- Sector
- IGMS Health Care
- QUIK Technology
- Exchange
- IGMS Nasdaq
- QUIK Nasdaq
- Market Cap
- IGMS 82.1M
- QUIK 87.3M
- IPO Year
- IGMS 2019
- QUIK 1997
- Fundamental
- Price
- IGMS $1.22
- QUIK $4.60
- Analyst Decision
- IGMS Hold
- QUIK Strong Buy
- Analyst Count
- IGMS 8
- QUIK 3
- Target Price
- IGMS $6.14
- QUIK $11.53
- AVG Volume (30 Days)
- IGMS 167.6K
- QUIK 146.2K
- Earning Date
- IGMS 05-07-2025
- QUIK 05-12-2025
- Dividend Yield
- IGMS N/A
- QUIK N/A
- EPS Growth
- IGMS N/A
- QUIK N/A
- EPS
- IGMS N/A
- QUIK N/A
- Revenue
- IGMS $2,679,000.00
- QUIK $20,112,000.00
- Revenue This Year
- IGMS $121.76
- QUIK $22.56
- Revenue Next Year
- IGMS $46.83
- QUIK $21.66
- P/E Ratio
- IGMS N/A
- QUIK N/A
- Revenue Growth
- IGMS 25.77
- QUIK N/A
- 52 Week Low
- IGMS $0.92
- QUIK $4.26
- 52 Week High
- IGMS $22.50
- QUIK $16.13
- Technical
- Relative Strength Index (RSI)
- IGMS 47.65
- QUIK 37.20
- Support Level
- IGMS $1.16
- QUIK $4.80
- Resistance Level
- IGMS $1.31
- QUIK $5.32
- Average True Range (ATR)
- IGMS 0.12
- QUIK 0.45
- MACD
- IGMS 0.03
- QUIK 0.04
- Stochastic Oscillator
- IGMS 76.92
- QUIK 29.06
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About QUIK QuickLogic Corporation
QuickLogic Corp provides programmable silicon and software platforms to enable its customers to develop custom hardware products in a fast time-to-market and cost-effective way. QuickLogic is a fabless semiconductor company with a product range: embedded FPGA (eFPGA) intellectual property (IP), low power, multi-core semiconductor system-on-chips (SoCs), discrete FPGAs, and AI software. The full range of platforms, software tools, and eFPGA IP enables the practical and efficient adoption of AI, voice, and sensor processing across Aerospace, and Defense, Consumer/Industrial IoT, and Consumer Electronics markets.